Replication analysis of rs75853687 (chromosome 5)
| . | Primary analysis (0 alloantibodies vs any alloantibodies) . | Multiantibody analysis (0 alloantibodies vs > 3 alloantibodies) . | ||||
|---|---|---|---|---|---|---|
| Cohort | Discovery (N = 267) | Replication (N = 130) | Meta-analysis | Discovery (N = 163) | Replication (N = 91) | Meta-analysis |
| MAF cases | 0.119 | 0.067 | 0.095 | 0.100 | ||
| MAF controls | 0.008 | 0.008 | 0.016 | 0.007 | ||
| Odds ratio (95% CI) | 16.5 (3.9-69.3) | 9.6 (1.2-78.3) | 6.5 (1.8-22.8) | 15.7 (1.7-144.5) | ||
| P | 8.36e-08 | .01 | 6.59e-09* | .0036 | .0086 | 9.43e-05 |
| . | Primary analysis (0 alloantibodies vs any alloantibodies) . | Multiantibody analysis (0 alloantibodies vs > 3 alloantibodies) . | ||||
|---|---|---|---|---|---|---|
| Cohort | Discovery (N = 267) | Replication (N = 130) | Meta-analysis | Discovery (N = 163) | Replication (N = 91) | Meta-analysis |
| MAF cases | 0.119 | 0.067 | 0.095 | 0.100 | ||
| MAF controls | 0.008 | 0.008 | 0.016 | 0.007 | ||
| Odds ratio (95% CI) | 16.5 (3.9-69.3) | 9.6 (1.2-78.3) | 6.5 (1.8-22.8) | 15.7 (1.7-144.5) | ||
| P | 8.36e-08 | .01 | 6.59e-09* | .0036 | .0086 | 9.43e-05 |
The results also show association that extends to individuals forming multiple antibodies (multiantibody analysis) in both cohorts with comparable magnitude and direction.